Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sabratek

This article was originally published in The Gray Sheet

  • News

Executive Summary

Retains restructuring firm Jay Alix & Associates to develop and implement restructuring plans. Also announced are the resignations of Chairman and CEO Shan Padda and Doron Levitas, vice-chariman and secretary; both will retain their positions as directors of the company. A representative of Jay Alix will be appointed acting CEO. The firm plans to report second quarter earnings "as soon as practicable" after auditors complete a previously announced review, but Sabratek was unable to meet the Aug. 20 deadline for its Form 10-Q. The law firm of Cohen, Milstein, Hausfeld & Toll announced Aug. 25 that they have filed a lawsuit against the company in Chicago federal court on behalf of persons who purchased Sabratek's common stock between May 11 and Aug. 23, 1999

Table

View full table

Tags:
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT012244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By